Submit Manuscript

International Journal of Pharmacology

Year: 2006 | Volume: 2 | Issue: 4 | Page No.: 388-393
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

ABSTRACT

Comparative study of markers of drug resistance in cancer tissues may be extremely helpful in selection of effective chemotherapeutic regimen. P-glycoprotein (P-gp) and Topoisomerase II α (Topo II α) are two fundamental proteins in multi-drug resistance phenomenon (MDR). This study determined the expression and significance of P-gp and Topo II α proteins in advanced gastric carcinomas and correlated molecular alterations with clinicopathological findings. Tissue samples of 35 patients with advanced type gastric adenocarcinoma were analyzed. Immunohistochemical techniques were applied using primary antibodies for P-gp or Topo II α and LSAB2 detection kit (Dako-Denmark). Positive immunostaining for P-gp and Topo II α were observed in 42.9% and 17.2% of tumor samples, respectively. Negative expressions of P-gp and TopoII were associated with sex (p = 0.035 and 0.0001) and histological grade (p = 0.021 and 0.0001), respectively. Unlike P-gp, an inverse relationship between Topo II α expression and size of tumors (p = 0.012) and lymphatic invasion (p = 0.013) were observed. Considering the key role of positive P-gp or negative Topo II α expression in MDR, it could be concluded that groups of patients with P-gp over expression (42.9%) or lack of Topo II α expression (82.8%) would less likely benefit from available chemotherapeutic regimens. Therefore, we highly recommend determination of tumor status for expression of tumor markers such as P-gp and Topo II α, before deciding about effective chemotherapeutic regimen for patients with gastric cancer.
PDF References Citation

How to cite this article

Sepideh Arbabi Bidgoli, Bagher Minaee, Mansoor Djamali Zavarehi, Shamileh Fouladdel and Ebrahim Azizi, 2006. P-glycoprotein and Topoisomerase II α Expression in Advanced Gastric Cancer Patients: Association with Clinicopathological Findings. International Journal of Pharmacology, 2: 388-393.

DOI: 10.3923/ijp.2006.388.393

URL: https://scialert.net/abstract/?doi=ijp.2006.388.393

Search

REFERENCES

  1. Bidgoli, A., M. Sepideh, G. Bagher, H. Mohammad and Z. Djamali et al., 2005. Expression of thymidylate synthase and thymidine phosphorylase as prognostic markers in advanced esophageal squamous cell carcinoma. Int. J. Pharmacol., 1: 104-111.
    CrossRefDirect Link
  2. Coleman, L.W., I.B. Bronstein and J.A. Holden, 2001. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-α and p53 in gastric carcinomas. Anticancer Res., 21: 1167-1172.
  3. Dhar, D.K., N. Nagasue, H. Yoshinwra, M. Tachibana, H. Tahara and H. Matsuura, 1995. Over expression of p-glycoprotein in AFP producing gastric carcinoma. J. Surg. Oncol., 60: 50-54.
    PubMedDirect Link
  4. Fan, K., D. Fan, L.F. Cheng and C. Li, 2000. Expression of multidrug resistance related markers in gastric cancers. Anticancer Res., 20: 4809-4814.
    Direct Link
  5. Fuji, H., N. Tanigawa, R. Muraoka, T. Shimoma and T. Suya, 1994. Clinical significance of Pgp expression and multidrug resistance assessed by in vitro thymidine incorporation assay in patients with gastric carcinoma. Gan. Kagaku Ryoho, 21: 2763-2770.
  6. Fuji, H., N. Tanigawa, R. Muraoka, T. Shimomatsua and T. Tanaka, 1995. Clinical significance of multidrug resistance and Pgp expression in patients with gastric carcinoma. J. Surg. Oncol., 58: 63-69.
  7. Katoh, M., 2004. Pharmacogenomics on gastric cancer. Cancer Biol. Ther., 3: 566-567.
    Direct Link
  8. Kim, W.Y. and L.Z. Benet, 2004. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm. Res., 21: 1284-1293.
    Direct Link
  9. Lim, L., M. Michael, G.B. Mann and T. Leong, 2005. Adjuvant therapy in gastric cancer. Clin. Oncol., 23: 6220-6232.
  10. Mizokuchi T. and K. Yamada, 1990. Expression of MDR1 gene in human gastric and colorectal carcinomas. J. Natl. Cancer Inst., 82: 1679-1683.
    PubMedDirect Link
  11. Rober, F.W. and W.R. Clarke, 2002. Statistical Methods for the Analysis of Biomedical Data. 2nd Edn., Wiley Intersciences Publisher, USA., ISBN: 978-0-471-39405-1, pp: 712.
  12. Rubin, E. and J.L. Farber, 1998. Pathology. 1st Edn., JB Lippincott, Philadelphia, USA.
  13. Ramesh, S., P. Shanthi, K.B. Krishnan, A.V. Shanthi, V. Taralakshmi and S. Subulakshmi, 2003. Multidrug resistance 1 gene expression in Indian patients with gastric carcinoma. Indian J. Gastroenterol., 22: 19-21.
  14. Schuetz, E.G., K.N. Furuya and J.D. Schuetz, 1995. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther., 275: 1011-1018.
    Direct Link
  15. Stege, A., A. Priebsch, C. Nieth and H. Lage, 2004. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther., 11: 699-706.
    PubMedDirect Link
  16. Yabuki, N., H. Sasano, K. Kato, S. Ohara and T. Toyota et al., 1996. Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am. J. Pathol., 149: 997-1007.
    PubMedDirect Link

Search

Related Articles

Leave a Comment

Your email address will not be published. Required fields are marked *